Literature DB >> 18155709

Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection.

Andrew C Bulmer1, Joanne T Blanchfield, Istvan Toth, Robert G Fassett, Jeff S Coombes.   

Abstract

Bilirubin is a potent antioxidant, however, uncertainty surrounds its physiological importance. Individuals with Gilbert's syndrome (GS) have increased circulating bilirubin and a reduced prevalence of cardiovascular disease (CVD). The aim of this study was to investigate mechanisms that may link bilirubin to protection from CVD seen in GS by examining markers of antioxidant and oxidative stress status and the susceptibility of serum to oxidation. Nine individuals with GS and twelve controls, matched for age, height and weight, were assessed for plasma antioxidant status, red blood cell antioxidant enzyme activities, plasma malondialdehyde, the susceptibility of serum to copper (Cu(2+)) induced oxidation and blood lipid profile. Individuals with GS had significantly elevated unconjugated bilirubin (GS: 26.0+/-6.4; control: 9.7+/-3.0 micromol/L; P<0.001), increased trolox equivalent antioxidant capacity (GS: 1.59+/-0.07; control: 1.52+/-0.07 mmol/L trolox Equ; P=0.035) and ferric reducing ability of plasma (GS: 1.09+/-0.16; control: 0.92+/-0.14 mmol/L Fe(2+) Equ; P=0.024). The lag phase of serum oxidation was significantly longer in the GS group (GS: 121.4+/-10.5; control: 106.8+/-14.6 min; P=0.020) and was positively correlated with the bilirubin concentration (r=0.451, P=0.040). A trend toward elevated HDL:LDL ratio was observed in GS (GS 0.96+/-0.31; control: 0.73+/-0.21; P=0.072). In summary, individuals with GS have an increased circulating antioxidant status and an improved resistance to serum oxidation which may partially explain their reduced prevalence of CVD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155709     DOI: 10.1016/j.atherosclerosis.2007.11.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  36 in total

Review 1.  Gilbert syndrome.

Authors:  Andrew Fretzayas; Maria Moustaki; Olga Liapi; Themistocles Karpathios
Journal:  Eur J Pediatr       Date:  2011-12-09       Impact factor: 3.183

Review 2.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

3.  Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration.

Authors:  Brian C Oveson; Takeshi Iwase; Sean F Hackett; Sun Young Lee; Shinichi Usui; Thomas W Sedlak; Solomon H Snyder; Peter A Campochiaro; Jennifer U Sung
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

4.  Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration.

Authors:  A C Bulmer; J S Coombes; J T Blanchfield; I Toth; R G Fassett; S M Taylor
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference.

Authors:  Patrick F McArdle; Brian W Whitcomb; Keith Tanner; Braxton D Mitchell; Alan R Shuldiner; Afshin Parsa
Journal:  BMC Cardiovasc Disord       Date:  2012-03-14       Impact factor: 2.298

Review 6.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

7.  Evaluating elevated bilirubin levels in asymptomatic adults.

Authors:  Lisa B VanWagner; Richard M Green
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

8.  Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition.

Authors:  David E Stec; Megan V Storm; Brandon E Pruett; Monette U Gousset
Journal:  Am J Hypertens       Date:  2013-03-12       Impact factor: 2.689

9.  In silico and crystallographic studies identify key structural features of biliverdin IXβ reductase inhibitors having nanomolar potency.

Authors:  Natasha M Nesbitt; Xiliang Zheng; Zongdong Li; José A Manso; Wan-Yi Yen; Lisa E Malone; Jorge Ripoll-Rozada; Pedro José Barbosa Pereira; Timothy J Mantle; Jin Wang; Wadie F Bahou
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

Review 10.  Heme oxygenase-1: a metabolic nike.

Authors:  Barbara Wegiel; Zsuzsanna Nemeth; Matheus Correa-Costa; Andrew C Bulmer; Leo E Otterbein
Journal:  Antioxid Redox Signal       Date:  2014-02-27       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.